Scynexis reports 'positive' interim Phase 2 results for ibrexafungerp
Scynexis announced positive results from the first interim efficacy analysis of the ongoing FURI study. FURI is a Phase 3 open-label study evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to or intolerant of currently available standards of care. Oral ibrexafungerp showed clinical benefits in 17 out of 20 patients, with 11 patients achieving a complete or partial response and six patients a stable disease response. These preliminary results support continued patient enrollment in the FURI study to build toward a future New Drug Application submission and potential approval through the Limited Population Pathway for Antibacterial and Antifungal Drugs. Oral ibrexafungerp was well-tolerated, with the most common treatment-related adverse events being gastrointestinal.